Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory ...

Could the same medication that causes people to lose weight hold the key to reducing drinking? In a new paper at the European ...

Trials have confirmed the efficacy of GLP-1 RAs in achieving clinically sustained weight loss in people with obesity without diabetes.

Adult patients taking Wegovy saw a reduced risk of experiencing a major adverse cardiovascular event within the first three months of treatment, according to a secondary analysis of the drug’s ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight ... showed a 20% reduction in major ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group. The Food and Drug Administration (FDA) has accepted for review ...

This led to the development of the wave of obesity-fighting drugs that are hotly discussed today: semaglutide, known better by its brand names Wegovy (for weight loss) or Ozempic (for Type 2 ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Other departments in the West Valley are joining together as part of a speed reduction task force. GLENDALE, Ariz. - Several Valley law enforcement agencies are teaming up to crackdown on speeding.